Core Viewpoint - The report serves as an independent financial advisory opinion on the 2025 Restricted Stock Incentive Plan of Shengxiang Biotechnology Co., Ltd, ensuring compliance with relevant laws and regulations while assessing the plan's feasibility and potential impact on the company's sustainable development and shareholder interests [1][2][18]. Group 1: Independent Financial Advisor's Role - The independent financial advisor, Shanghai Miaodao Enterprise Management Consulting Co., Ltd, was commissioned to provide an advisory report based on the 2025 Restricted Stock Incentive Plan [1]. - The advisor conducted due diligence and confirmed that the professional opinions expressed align with the disclosed documents of the company [2][3]. Group 2: Incentive Plan Overview - The incentive plan involves granting 1,192,600 restricted stocks, accounting for approximately 0.21% of the company's total share capital of 579,388,006 shares [5][6]. - The plan is designed to motivate key employees of the wholly-owned subsidiary, Zhongshan Shengxiang Haiji Biotechnology Co., Ltd, and is structured to align the interests of the company, shareholders, and core team members [23]. Group 3: Conditions and Terms - The grant price for the restricted stocks is set at 16.40 RMB per share, which is 79.46% of the average trading price on the day before the plan was announced [10][11]. - The plan includes specific performance targets for the subsidiary, with net profit goals of no less than 140 million RMB for 2025 and 180 million RMB for 2026 [12][16]. Group 4: Compliance and Feasibility - The plan complies with the relevant regulations, including the Management Measures and the Self-Regulatory Guidelines, ensuring that the granting conditions and procedures are legally sound [18][19]. - The independent financial advisor confirmed that the plan's implementation would positively impact the company's sustainable operations and shareholder equity [23][24]. Group 5: Performance Evaluation - The performance evaluation system for the incentive plan includes both company-level and individual-level assessments, ensuring a comprehensive evaluation of the employees' contributions [26]. - The plan's structure is designed to motivate employees while ensuring that the interests of shareholders are not compromised [25][26].
圣湘生物: 上海妙道企业管理咨询有限公司关于圣湘生物科技股份有限公司2025年限制性股票激励计划(草案)之独立财务顾问报告